Supplementary Data from Genomic Profiling of Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer after Progression on First-line Osimertinib: Phase II ORCHARD Study

Résumé fourni par la source

Supplementary Material Supplementary Table S1. Representativeness of study participants. Supplementary Table S2. Baseline demographic and clinical characteristics of patients with transformed histology. Supplementary Table S3. MET amplification detected by tissue and plasma NGS in patients with <5% EGFR VAF. Supplementary Table S4. MET amplification detected by tissue and plasma NGS in all patients. Supplementary Table S5. MET amplification detected by tissue and plasma NGS in patients with ≥5% EGFR VAF. Supplementary Table S6. Co-occurrence of resistance alterations with EGFR mutations detected via tissue NGS. Supplementary Figure S1. ORCHARD study design. Supplementary Figure S2. Plasma-based resistance mechanisms to first-line osimertinib identified via NGS in samples with transformed histology. Supplementary Figure S3. Plasma-based EGFR landscape of samples with at least one atypical or secondary resistance EGFR mutation to first-line osimertinib.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.